Synthesis and biological evaluation of novel thiazolyl-coumarin derivatives as potent histone deacetylase inhibitors with antifibrotic activity
Author
dc.contributor.author
Pardo-Jiménez, Viviana
Author
dc.contributor.author
Navarrete-Encina, Patricio
Author
dc.contributor.author
Díaz-Araya, Guillermo
Admission date
dc.date.accessioned
2019-10-15T12:25:25Z
Available date
dc.date.available
2019-10-15T12:25:25Z
Publication date
dc.date.issued
2019
Cita de ítem
dc.identifier.citation
Molecules, Volumen 24, Issue 4, 2019,
Identifier
dc.identifier.issn
14203049
Identifier
dc.identifier.other
10.3390/molecules24040739
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/171681
Abstract
dc.description.abstract
New histone deacetylases (HDAC) inhibitors with low toxicity to non-cancerous cells, are a prevalent issue at present because these enzymes are actively involved in fibrotic diseases. We designed and synthesized a novel series of thiazolyl-coumarins, substituted at position 6 (R = H, Br, OCH3), linked to classic zinc binding groups, such as hydroxamic and carboxylic acid moieties and alternative zinc binding groups such as disulfide and catechol. Their in vitro inhibitory activities against HDACs were evaluated. Disulfide and hydroxamic acid derivatives were the most potent ones. Assays with neonatal rat cardiac fibroblasts demonstrated low cytotoxic effects for all compounds. Regarding the parameters associated to cardiac fibrosis development, the compounds showed antiproliferative effects, and triggered a strong decrease on the expression levels of both α-SMA and procollagen I. In conclusion, the new thiazolyl-coumarin derivatives inhibit HDAC activity and decre